The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-27. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
== Related legacy/cover bands featuring former King Crimson members == Since the early 2000s, several bands containing former, recent or current King Crimson members have toured and recorded, performing King Crimson music. Active between 2002 and 2005, the 21st Century Schizoid Band reunited several former King Crimson members who had played on the band's first four albums. The band featured Ian McDonald, Mel Collins, Peter Giles and Michael Giles (the latter subsequently replaced by Ian Wallace), and was fronted by Jakko Jakszyk, a decade prior to his own recruitment into King Crimson. The band engaged in several tours, played material from King Crimson's '60s and '70s catalogue, and recorded several live albums. The band disbanded upon Wallace's death in 2007. Since 2007, Tony Levin has led the trio Stick Men, which also features Pat Mastelotto. The band was initially completed by Chapman Stick player Michael Bernier, replaced in 2010 by touch guitarist and former Fripp student Markus Reuter. This band includes (and reinterprets) King Crimson compositions in their live sets. Reuter and Mastelotto also play together as a duo (previously called "Tuner"), within which they have been known to rework the mid-1980s King Crimson instrumental "Industry" live. Starting in 2023, Reuter, Mastelotto and Trey Gunn revived the moniker "Tuner" (re-styled as "Tu-ner") to perform music from the Double Duo era of King Crimson, plus material from each of their respective solo and combined careers.
=== Access to healthcare === In 2021, the French Senate's Delegation for Women's Rights reported that women's health was not considered a priority in rural areas, where medical desertification limits access to gynecological care. This can result in delayed care and inadequate cancer screening. France has faced a shortage of medical gynecologists, with some departments lacking them entirely. Medical gynecology, a discipline distinct from obstetrics and specific to France, saw a halt in specialist training from 1984 to 2003 as the country considered aligning with other European healthcare systems that do not maintain this distinction.
DM is paraneoplastic in up to 40% of cases, most commonly in association with underlying malignancy in patients with anti–TIF1γ autoantibodies. A majority of patients with paraneoplastic dermatomyositis harbor somatic mutations or other genetic alterations in tumor genes encoding the target autoantigens of their corresponding autoantibodies, suggesting that, in this context, autoantibody production arises secondary to an anti-tumor immune response that fails to achieve effective tumor control.The most commonly associated cancers are ovarian cancer, breast cancer, and lung cancer overall, but the most frequent associations can vary depending on patient race or ethnicity. Inherited genetic factors confer a predisposition to developing these diseases, and HLA subtypes HLA-DR3, HLA-DR52, and HLA-DR6 seem to create a disposition to DM.
Sources: en.wikipedia.org
==== Developing SASO ==== Following the 1968 NUSAS conference in Johannesburg, many of its members attended a July 1968 conference of the University Christian Movement at Stutterheim. There, the black African members decided to hold a December conference to discuss the formation of an independent black student group. The South African Students' Organisation (SASO) was officially launched at a July 1969 conference at the University of the North; there, the group's constitution and basic policy platform were adopted. The group's focus was on the need for contact between centres of black student activity, including through sport, cultural activities, and debating competitions. Though Biko played a substantial role in SASO's creation, he sought a low public profile during its early stages, believing that this would strengthen its second level of leadership, such as his ally Barney Pityana. Nonetheless, he was elected as SASO's first president; Pat Matshaka was elected vice president and Wuila Mashalaba elected secretary. Durban became its de facto headquarters.
=== Pharmacokinetics === When administered orally, CBN demonstrates a similar metabolism to Δ9-THC, with the primary intoxicating metabolite being produced through a hydroxylation reaction that occurs in the liver. The active metabolite generated via this process is called 11-OH-CBN, which is around two times as potent as CBN, and has demonstrated activity as a weak CB2 antagonist. This metabolism starkly contrasts that of standard cannabis edibles in terms of potency, given that 11-OH-THC has been reported to have 10× the potency of Δ9-THC. Due to high lipophilicity and first-pass metabolism, there is low bioavailability of CBN and other cannabinoids following oral administration. CBN metabolism is mediated in part by CYP450 isoforms 2C9 and 3A4. The metabolism of CBN may be catalyzed by UGTs (UDP-glucuronosyltransferases), with a subset of UGT isoforms (1A7, 1A8, 1A9, 1A10, 2B7) identified as potential substrates associated with CBN glucuronidation. The bioavailability of CBN following administration via inhalation (e.g., smoking or vaporizing) is approximately 40% that of intravenous administration. A small study of six cannabis users found a highly variable half life of 32 ± 17 hours upon intravenous administration. Similar to CBD, CBN is metabolized by the CYP2C9 and CYP3A4 liver enzymes and thus the half-life is sensitive to genetic factors that effect the levels of these enzymes.
=== Heat-flux DSC === With Heat-flux DSC, the changes in heat flow are calculated by integrating the ΔTref- curve. For this kind of experiment, a sample and a reference crucible are placed on a sample holder with integrated temperature sensors for temperature measurement of the crucibles. This arrangement is located in a temperature-controlled oven. Unlike the traditional design, the special feature of heat-flux DSC is that it uses flat temperature sensors placed vertically around a flat heater. This setup makes it possible to have a small, light, and low-heat capacity structure while still working like a regular DSC oven.
The IPCC Sixth Assessment Report summarized the scientific knowledge in 2021 for the future of ENSO as follows: "In the long term, it is very likely that the precipitation variance related to El Niño–Southern Oscillation will increase". The scientific consensus is also that "it is very likely that rainfall variability related to changes in the strength and spatial extent of ENSO teleconnections will lead to significant changes at regional scale".
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.